Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 162

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 162
---
16; for a woman, the risk is about 1 in 17. These numbers include both people who smoke and those who don’t smoke. For people who smoke, the risk is much higher, while for those who don’t, the risk is lower.

| ● | Black men are about 12% more likely to develop                                              
 lung cancer than White men. The rate is about 16% lower in Black women than in White women. |

| ● | Black and White women have lower rates than men,                                                                                       
 but the gap is closing. The lung cancer rate has been dropping among men over the past few decades, but only for about the past decade 
 in women.                                                                                                                              |

| ● | Despite their overall risk of lung cancer being                   
 higher, Black men are less likely to develop SCLC than White men. |

Statistics on survival in people with lung cancer vary depending on the type of lung cancer, the stage (extent) of the cancer when it is diagnosed, and other factors. 5-year relative survival rates for non-small cell lung cancer These numbers are based on people diagnosed with NSCLC between 2012 and 2018.

| SEER stage               |     | 5-year relative survival rate |
| Localized                |     | 65%                           |
| Regional                 |     | 37%                           |
| Distant                  |     | 9%                            |
| All SEER stages combined |     | 28%                           |

Our therapeutic approach and development program We anticipate the design of the clinical development program for CER-1236 to enable our evaluation of its therapeutic utility in treating both hematologic and solid tumors, as the capacity of a single therapeutic construct to provide clinical benefit across this diversity of tumor types would represent a significant advance in cancer immunotherapy. Due to the therapy’s novel mechanism of action, engaging both the innate and the adaptive immune response, and the broad expression profile of PS on a variety of hematologic and solid tumors, we intend to employ an adaptive Phase 1 trial design to evaluate patient response to CER-1236. As such, the dosing protocol will emphasize a gradual increase in the delivered dose with the objective of achieving a clinical signal, while ensuring patient safety. We also intend our Phase 1 trial design to enable an evaluation of appropriate dosing strategies to optimize CER-T engagement and proliferation. 104 We believe, subject to discussions with the FDA and other regulatory authorities, that there may be a full development path to registration and use in